Adult Leukemia Research Center

成人白血病研究中心

• 批准号: 8733521
• 负责人: FREDERICK APPELBAUM
• 金额: $ 409.87万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-22 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8733521
• 关键词: Address; Adoptive Immunotherapy; Affinity; Allogenic; B lymphoid malignancy; Biometry; CD8B1 gene; Cell physiology; Cells; Clinical; Clinical Research; Clinical Trials; Cytomegalovirus; Diagnostic; Disease; Disease Progression; Goals; Hematologic Neoplasms; Hematopoietic; Hematopoietic Neoplasms; Human Herpesvirus 4; Immunogenetics; Incidence; Individual; Laboratory Study; Learning; Lymphoblastic Leukemia; Malignant - descriptor; Malignant Neoplasms; Methodology; Methods; Molecular; Mutagenesis; Mutate; Myeloproliferative disease; Outcome; Patients; Pre-Clinical Model; Procedures; Program Research Project Grants; Recurrence; Relapse; Research; Research Personnel; Role; Safety; Series; Severities; Single Nucleotide Polymorphism; T-Cell Receptor; T-Lymphocyte; Testing; Toxic effect; Transplant Recipients; Transplantation; United States; Work; adult leukemia; allotransplant; base; cancer immunotherapy; chimeric antigen receptor; clinical efficacy; follow-up; graft vs host disease; hematopoietic cell transplantation; improved; insight; leukemia; mouse model; novel; novel therapeutics; pre-clinical research; prevent; programs; success; tool

DESCRIPTION (provided by applicant): The overall goal of this program project is to improve allogeneic hematopoietic cell transplantation (HCT) as treatment for hematological malignancies. Specifically we proposed laboratory and clinical studies to broaden the availability of transplantation, to decrease the incidence and severity of graft-versus-host disease, and to reduce the incidence of malignant disease recurrence post transplant. Four individual projects are proposed: 1. Immunogenetics of Graft-versus-host Disease. 2. Nonmyeloablative Hematopoietic Cell Allotransplants. 3. Specific Adoptive Immunotherapy of Myeloid Malignancy. 4. Targeting T Cell Reactivity for Leukemia Eradication. In addition, core support is requested in biostatistics, molecular diagnostics, cell processing, long-term follow-up, and administration. Our ability to successfully carry out the proposed work is greatly benefited by: (1) the existence of a large group of investigators all focused on the general topic of HCT; (2) strong preclinical research programs at our Center in support of this topic; and, (3) treatment of >500 transplant patients at our Center each year

描述（由申请人提供）：本项目的总体目标是改善异基因造血细胞移植（HCT）治疗血液恶性肿瘤。具体而言，我们建议进行实验室和临床研究，以扩大移植的可用性，降低移植物抗宿主病的发生率和严重程度，并减少移植后恶性疾病复发的发生率。 建议开展四个单独的项目： 1.移植物抗宿主病的免疫遗传学。 2.非清髓性造血细胞同种异体移植。 3.骨髓瘤的特异性免疫治疗 4.靶向T细胞反应性以根除白血病。 此外，还需要在生物统计、分子诊断、细胞处理、长期随访和管理方面提供核心支持。 我们能够成功地开展拟议的工作是非常有益的：（1）存在一个大的研究小组，都集中在HCT的一般主题;（2）强大的临床前研究计划，在我们的中心，以支持这一主题;和，（3）治疗>500移植患者在我们的中心每年